tiprankstipranks
Trending News
More News >

CStone Pharmaceuticals Updates Phase III Study on Nofazinlimab for Liver Cancer

Story Highlights
CStone Pharmaceuticals Updates Phase III Study on Nofazinlimab for Liver Cancer

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from CStone Pharmaceuticals ( (HK:2616) ).

CStone Pharmaceuticals has announced an update on their global multicenter Phase III study of nofazinlimab in hepatocellular carcinoma (HCC). The study, which involved 74 sites worldwide, evaluated the efficacy and safety of nofazinlimab combined with lenvatinib against a placebo-lenvatinib combination in patients with unresectable or metastatic HCC. The results showed a compelling trend in overall survival and meaningful improvements in progression-free survival and objective response rate, although statistical significance was not reached. Nofazinlimab demonstrated a manageable safety profile, with no new safety signals observed. CStone plans to engage with regulatory authorities to explore the registration pathway for this combination therapy, potentially impacting the company’s operations and positioning in the oncology market.

More about CStone Pharmaceuticals

CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focused on developing anti-cancer therapies. With a commitment to addressing unmet medical needs in China and globally, CStone has launched four innovative drugs and secured approvals for 16 new drug applications covering nine indications. The company’s pipeline includes 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines.

Average Trading Volume: 12,120,952

Technical Sentiment Signal: Buy

Current Market Cap: HK$5.62B

See more insights into 2616 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1